Sandbox g15: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
(44 intermediate revisions by the same user not shown) | |||
Line 65: | Line 65: | ||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | * Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | ||
* Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/ kg/24 hr divided q 8 hr IV or IM (1, | * Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 100 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g) | ||
* Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM | * Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM | ||
* Adults: 250-500 mg q 4-8 hr IV or IM | * Adults: 250-500 mg q 4-8 hr IV or IM | ||
Line 107: | Line 107: | ||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | * Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | ||
* Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1, | * Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 120 mg/kg/24 hr divided q 6-8 hr IV or IM (> 2,000 g) | ||
* Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM | * Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM | ||
* Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr) | * Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr) | ||
Line 142: | Line 142: | ||
* Rash | * Rash | ||
* Eosinophilia | * Eosinophilia | ||
* Serum sickness | * Serum sickness-like reaction | ||
|- | |- | ||
| '''Cefadroxil''' | | '''Cefadroxil''' | ||
Line 451: | Line 451: | ||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 10 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | * Neonates (postnatal age ≤ 7 days): 10 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | ||
* Neonates (postnatal age > 7 days): 10 mg/kg/24 hr IV or IM divided q 12 hr (≤ 1,200 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (1, | * Neonates (postnatal age > 7 days): 10 mg/kg/24 hr IV or IM divided q 12 hr (≤ 1,200 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 20 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | ||
* Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO | * Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO | ||
* Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO) | * Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO) | ||
Line 458: | Line 457: | ||
* Diarrhea | * Diarrhea | ||
* Nausea | * Nausea | ||
* | * Pseudomembranous colitis | ||
* Rash | * Rash | ||
|- | |- | ||
| '''Cloxacillin''' | |||
| | | | ||
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci | |||
| | | | ||
* Children: 50-100 mg/kg/24 hr divided q 6 hr PO | |||
* Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr) | |||
Children: 50-100 mg/kg/24 hr divided q 6 hr PO | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
|- | |- | ||
| '''Trimethoprim-Sulfamethoxazole''' | |||
| | | | ||
* Shigella | |||
* Legionella | |||
* Nocardia | |||
* Chlamydia | |||
* Pneumocystis jirovecii | |||
| | | | ||
* Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO | |||
* Adults: 160 mg TMP q 12 hr PO | |||
Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO | |||
| | | | ||
* Rash | |||
* Erythema multiforme | |||
Stevens-Johnson syndrome | * Stevens-Johnson syndrome | ||
* Nausea | |||
* Leukopenia | |||
|- | |- | ||
| '''Demeclocycline''' | |||
| | | | ||
* Gram-positive cocci except Enterococcus | |||
* Gram-negative bacilli | |||
* Anaerobes | |||
* Borrelia burgdorferi | |||
* Mycoplasma | |||
* Chlamydia | |||
| | | | ||
* Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO | |||
* Adults: 150 mg PO q 6-8 hr | |||
Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO | |||
| | | | ||
* Teeth staining | |||
* Photosensitivity | |||
* Diabetes insipidus | |||
* Nausea | |||
* Vomiting | |||
* Diarrhea | |||
|- | |- | ||
| '''Dicloxacillin''' | |||
| | | | ||
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci | |||
| | | | ||
* Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO | |||
* Adults: 125-500 mg q 6 hr PO | |||
Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
|- | |- | ||
| '''Doripenem''' | |||
| | | | ||
* Gram-positive cocci | |||
* Gram-negative bacilli including P. aeruginosa | |||
* Anaerobes | |||
| | | | ||
* Adults: 500 mg q 8 hr IV | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
|- | |- | ||
| '''Doxycycline''' | |||
| | | | ||
* Gram-positive cocci except Enterococcus | |||
* Gram-negative bacilli | |||
* Anaerobes | |||
* B. burgdorferi | |||
* Mycoplasma | |||
* Chlamydia | |||
| | | | ||
* Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200 mg/24 hr) | |||
* Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV | |||
Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200 | |||
Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV | |||
| | | | ||
* Teeth staining | |||
* Photosensitivity | |||
* Nausea | |||
* Vomiting | |||
* Diarrhea | |||
|- | |- | ||
| '''Erythromycin''' | |||
| | | | ||
* Gram-positive organisms | |||
* Corynebacterium diphtheriae | |||
* Mycoplasma pneumoniae | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 20 mg/kg/24 hr divided q 12 hr PO | |||
* Neonates (postnatal age > 7 days): 20 mg/kg/24 hr divided q 12 hr PO (< 1,200 g); 30 mg/kg/24 hr divided q 8 hr PO (> 1,200 g) | |||
Neonates | * Children: Usual max dose 2 g/24 hr. Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV. Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV | ||
* Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO | |||
30 mg/kg/24 hr divided q 8 hr PO ( | |||
Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV. | |||
Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV | |||
Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO | |||
| | | | ||
* Cramping | |||
* Nausea | |||
* Vomiting | |||
* Diarrhea | |||
* Hypertrophic pyloric stenosis | |||
|- | |- | ||
| '''Gentamicin''' | |||
| | | | ||
* E. coli | |||
* Klebsiella | |||
* Proteus | |||
* Enterobacter | |||
* Serratia | |||
* Pseudomonas | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q 12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 32.5 mg/kg q 8 hr IV or IM (> 2,000 g) | |||
Neonates | * Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV once daily | ||
* Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM | |||
12-18 hr IV or IM; | |||
Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM | |||
Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM | |||
| | | | ||
* Ototoxicity | |||
* Nephrotoxicity | |||
|- | |- | ||
| '''Imipenem-Cilastatin''' | |||
| | | | ||
* Gram-positive cocci | |||
* Gram-negative bacilli including P. aeruginosa | |||
* Anaerobes | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 20 mg/kg q 18-24 hr IV or IM (< 1,200 g); 40 mg/kg divided q 12 hr IV or IM (> 1,200 g) | |||
* Neonates (postnatal age > 7 days): 40 mg/kg q 12 hr IV or IM (< 2,000 g); 60 mg/kg q 8 hr IV or IM (> 2,000 g) | |||
* Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM | |||
* Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr) | |||
Neonates | |||
Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM | |||
Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Nausea | |||
* Seizures | |||
|- | |- | ||
| '''Linezolid''' | |||
| | | | ||
* Staphylococcus | |||
* Streptococcus | |||
* E. faecium | |||
* Enterococcus faecalis | |||
| | | | ||
* Children: 10 mg/kg q 12 hr IV or PO | |||
* Adults: Pneumonia: 600 mg q 12 hr IV or PO | |||
Children: 10 mg/kg q 12 hr IV or PO | |||
Adults: Pneumonia: 600 mg q 12 hr IV or PO | |||
| | | | ||
* Bone marrow suppression | |||
* Pseudomembranous colitis | |||
* Nausea | |||
* Diarrhea | |||
* Headache | |||
|- | |- | ||
| '''Loracarbef''' | |||
| | | | ||
* S. aureus | |||
* Streptococcus | |||
* H. influenzae | |||
* M. catarrhalis | |||
* E. coli | |||
* Klebsiella | |||
* Proteus | |||
| | | | ||
* Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g) | |||
* Adults: 200-400 mg q 12 hr PO (max dose: 800 mg/24 hr) | |||
Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
|- | |- | ||
| '''Meropenem''' | |||
| | | | ||
* Gram-positive cocci | |||
* Gram-negative bacilli including P. aeruginosa | |||
* Anaerobes | |||
| | | | ||
* Children: 60 mg/kg/24 hr divided q 8 hr IV | |||
* Adults: 1.5-3 g q 8 hr IV | |||
Children: 60 mg/kg/24 hr divided q 8 hr IV | |||
Adults: 1.5-3 g q 8 hr IV | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
|- | |- | ||
| '''Metronidazole''' | |||
| | | | ||
* Anaerobes | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 7.5 mg/kg 48 hr PO or IV (< 1,200 g); 7.5 mg/kg/24 hr q 24 hr PO or IV (1,200–2,000 g); 15 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 5 mg/kg/24 hr divided q 12 hr PO or IV (< 2,000 g); 30 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g) | |||
Neonates | * Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV | ||
* Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr) | |||
Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV | |||
Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr) | |||
| | | | ||
* Dizziness | |||
* Seizures | |||
* Metallic taste | |||
* Nausea | |||
* Hypoprothrombinemia | |||
* Disulfiram-like reaction | |||
|- | |- | ||
| '''Mezlocillin''' | |||
| | | | ||
* E. coli | |||
* Enterobacter | |||
* Serratia | |||
* Bacteroides | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 12 hr IV | |||
* Neonates (postnatal age > 7 days): 225 mg/kg divided q 8 hr IV | |||
* Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV | |||
* Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr) | |||
Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV | |||
Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Liver transaminases elevation | |||
|- | |- | ||
| '''Mupirocin''' | |||
| | | | ||
* Staphylococcus | |||
* Streptococcus | |||
| | | | ||
* Topical application to the skin 2-4 times per day | |||
Topical application | |||
| | | | ||
* Itching | |||
|- | |- | ||
| '''Nafcillin''' | |||
| | | | ||
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 75 mg/kg/q 8 hr IV (< 2,000 g); 100 mg/kg divided q 6-8 hr IV (> 2,000 g) | |||
Neonates | * Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV | ||
* Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr) | |||
Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV | |||
Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Phlebitis | |||
* Neutropenia | |||
|- | |- | ||
| '''Nalidixic acid''' | |||
| | | | ||
* E. coli | |||
* Enterobacter | |||
* Klebsiella | |||
* Proteus | |||
| | | | ||
* Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO | |||
* Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO | |||
Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO | |||
Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO | |||
| | | | ||
* Vertigo | |||
* Dizziness | |||
* Rash | |||
|- | |- | ||
| '''Neomycin''' | |||
| | | | ||
* Gastrointestinal flora | |||
| | | | ||
* Infants: 50 mg/kg/24 hr divided q 6 hr PO | |||
* Children: 50-100 mg/kg/24 hr divided q 6-8 hr PO | |||
Infants: 50 mg/kg/24 hr divided q 6 hr PO | * Adults: 500-2,000 mg/dose q 6-8 hr PO | ||
| | | | ||
* Cramping | |||
* Diarrhea | |||
* Rash | |||
* Ototoxicity | |||
* Nephrotoxicity | |||
|- | |- | ||
| '''Nitrofurantoin''' | |||
| | | | ||
* Gram-positive pathogens | |||
* Gram-negative pathogens | |||
| | | | ||
* Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose: 400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr) | |||
* Adults: 50-100 mg/24 hr divided q 6 hr PO | |||
Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose: | |||
400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr) | |||
Adults: 50-100 mg/24 hr divided q 6 hr PO | |||
| | | | ||
* Vertigo | |||
* Dizziness | |||
* Rash | |||
* Jaundice | |||
* Interstitial pneumonitis | |||
|- | |- | ||
| '''Ofloxacin''' | |||
| | | | ||
* Gram-positive pathogens | |||
* Gram-negative pathogens | |||
* Anaerobes | |||
* Chlamydia trachomatis | |||
| | | | ||
* Child (< 12 yr): Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then 1-2 drops qid for 5 days. Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days. Otitis externa: 5 drops into affected ear bid for 10 days | |||
* Child (> 12 yr) and adults: Ophthalmic solution doses same as for younger children. Otitis externa: 10 drops bid for 10–14 days as for younger children | |||
Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then | |||
1-2 drops qid for 5 days. | |||
Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days. | |||
Otitis externa | |||
| | | | ||
* Burning | |||
* Stinging | |||
* Eye redness | |||
* Dizziness | |||
|- | |- | ||
| '''Oxacillin''' | |||
| | | | ||
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV (< 2,000 g); 75 mg/kg/24 hr IV divided q 8 hr IV (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV divided q 12 hr IV (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV (1,200–2,000 g); 100 mg/kg/24 hr IV divided q 6 hr IV (> 2,000 g) | |||
Neonates | * Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV | ||
* Children: PO 50-100 mg/kg/24 hr divided q 4-6 hr IV | |||
100 mg/kg/24 hr IV divided q 6 hr IV | * Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr) | ||
Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV | |||
Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Neutropenia | |||
|- | |- | ||
| '''Penicillin G''' | |||
| | | | ||
* S. pneumoniae | |||
* Group A Streptococcus | |||
* N. gonorrhoeae | |||
* N. meningitidis | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 50,000 units/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75,000 units/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 50,000 units/kg/24 hr divided q 12 hr IV (< 1,200 g); 75,000 units/kg/24 hr q 8 hr IV (1,200–2,000 g); 100,000 units/kg/24 hr divided q 6 hr IV (> 2,000 g) | |||
* Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr) | |||
* Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM | |||
Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr) | |||
Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Allergy | |||
* Seizures | |||
|- | |- | ||
| '''Penicillin G, benzathine''' | |||
| | | | ||
* Group A Streptococcus | |||
| | | | ||
* Neonates: 50,000 units/kg IM once | |||
* Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose: 1.2-2.4 million units/dose) | |||
Neonates | * Adults: 1.2 million units IM q 3-4 wk | ||
Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose: | |||
1.2-2.4 million units/dose) | |||
Adults: 1.2 million units IM q 3-4 wk | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Allergy | |||
|- | |- | ||
| '''Penicillin G, procaine''' | |||
| | | | ||
* Gram-positive pathogens | |||
| | | | ||
* Neonates: 50,000 units/kg/24 hr IM | |||
* Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose: 4.8 million units/dose) | |||
Neonates | * Adults: 0.6-4.8 million units q 12-24 hr IM | ||
Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose: | |||
4.8 million units/dose) | |||
Adults: 0.6-4.8 million units q 12-24 hr IM | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Allergy | |||
|- | |- | ||
| '''Penicillin V''' | |||
| | | | ||
* S. pneumoniae | |||
* N. gonorrhoeae | |||
* N. meningitidis | |||
| | | | ||
* Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO | |||
* Adults: 125-500 mg q 6-8 hr PO (max dose: 3 g/24 hr) | |||
Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Allergy | |||
|- | |- | ||
| '''Piperacillin''' | |||
| | | | ||
* E. coli | |||
* Enterobacter | |||
* Serratia | |||
* P. aeruginosa | |||
* Bacteroides | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV | |||
* Neonates (postnatal age > 7 days): 200 mg/kg divided q 6-8 hr IV | |||
Neonates | * Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV | ||
* Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV | |||
Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV | |||
Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Serum sickness-like reaction | |||
|- | |- | ||
| '''Piperacillin-Tazobactam''' | |||
| | | | ||
* S. aureus | |||
* H. influenzae | |||
* E. coli | |||
* Enterobacter | |||
* Serratia | |||
* Acinetobacter | |||
* P. aeruginosa | |||
* Bacteroides | |||
| | | | ||
* Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM | |||
* Adults: 3.375 g q 6-8 hr IV or IM | |||
Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
|- | |- | ||
| '''Quinupristin-Dalfopristin''' | |||
| | | | ||
* E. faecium, vancomycin-resistant | |||
* S. aureus, methicillin-resistant | |||
| | | | ||
* Children and adults: 7.5 mg/kg q 8 hr IV | |||
Children and adults | |||
| | | | ||
* Pain | |||
* Edema | |||
* Phlebitis | |||
* Nausea | |||
* Diarrhea | |||
|- | |- | ||
| '''Sulfadiazine''' | |||
| | | | ||
* E. coli | |||
* P. mirabilis | |||
* Klebsiella | |||
| | | | ||
* Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO with folinic acid | |||
* Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid | |||
Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO | |||
Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid | |||
| | | | ||
* Rash | |||
* Stevens-Johnson syndrome | |||
* Nausea | |||
* Leukopenia | |||
* Crystalluria | |||
|- | |- | ||
| '''Sulfamethoxazole''' | |||
| | | | ||
* Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections | |||
| | | | ||
* Children: 50-60 mg/kg/24 hr divided q 12 hr PO | |||
* Adults: 1 g/dose q 12 hr PO (max dose: 3 g/24 hr) | |||
Children: 50-60 mg/kg/24 hr divided q 12 hr PO | |||
| | | | ||
* Rash | |||
* Stevens-Johnson syndrome | |||
* Nausea | |||
* Leukopenia | |||
* Crystalluria | |||
|- | |- | ||
| '''Sulfisoxazole''' | |||
| | | | ||
* Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections | |||
| | | | ||
* Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr) | |||
* Adults: 4-8 g/24 hr divided q 4-6 hr PO | |||
Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr) | |||
Adults: 4-8 g/24 hr divided q 4-6 hr PO | |||
| | | | ||
* Rash | |||
* Stevens-Johnson syndrome | |||
* Nausea | |||
* Leukopenia | |||
* Crystalluria | |||
|- | |- | ||
| '''Ticarcillin''' | |||
| | | | ||
* E. coli | |||
* Enterobacter | |||
* Serratia | |||
* P. aeruginosa | |||
* Bacteroides | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV | |||
* Neonates (postnatal age > 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV (< 1,200 g); 150 mg/kg/24 hr divided q 12 hr IV (1,200–2,000 g); 300 mg/kg/24 hr divided q 6-8 hr IV (> 2,000 g) | |||
Neonates | * Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV | ||
* Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr) | |||
Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV | |||
Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Liver transaminases elevation | |||
|- | |- | ||
| '''Ticarcillin-Clavulanate''' | |||
| | | | ||
* S. aureus | |||
* H. influenzae | |||
* Enterobacter | |||
* E. coli | |||
* Serratia | |||
* P. aeruginosa | |||
* Acinetobacter | |||
* Bacteroides | |||
| | | | ||
* Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM | |||
* Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr) | |||
Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM | |||
Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr) | |||
| | | | ||
* Rash | |||
* Eosinophilia | |||
* Liver transaminases elevation | |||
|- | |- | ||
| '''Tigecycline''' | |||
| | | | ||
* Enterobacteriaceae including ESBL producers | |||
* Streptococcus | |||
* Staphylococcus | |||
* Anaerobes | |||
| | | | ||
* Adults: 100 mg loading dose followed by 50 mg q 12 hr IV | |||
Adults: 100 mg loading dose followed by 50 mg q 12 hr IV | |||
| | | | ||
* Photosensitivity | |||
* Hypersensitivity | |||
* Hepatic impairment | |||
|- | |- | ||
| '''Tobramycin''' | |||
| | | | ||
* E. coli | |||
* Klebsiella | |||
* Enterobacter | |||
* Serratia | |||
* Proteus | |||
* Pseudomonas | |||
| | | | ||
* Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 2.5 mg/kg q 8 hr IV or IM (> 2,000 g) | |||
Neonates | * Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV | ||
* Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM | |||
Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM | |||
Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM | |||
| | | | ||
* Ototoxicity | |||
* Nephrotoxicity | |||
|- | |- | ||
| '''Trimethoprim''' | |||
| | | | ||
* E. coli | |||
* Klebsiella | |||
* P. mirabilis | |||
* Enterobacter | |||
* P. jirovecii | |||
| | | | ||
* Children (< 12 yr): 4-6 mg/kg/24 hr divided q 12 hr PO | |||
* Children (> 12 yr) and adults: 100-200 mg q 12 hr PO | |||
Children | |||
| | | | ||
* Megaloblastic anemia | |||
* Bone marrow suppression | |||
* Nausea | |||
* Epigastric distress | |||
* Rash | |||
|- | |- | ||
| '''Vancomycin''' | |||
| | | | ||
* Gram-positive pathogens including Staphylococcus, S. pneumoniae, and Enterococcus | |||
* C. difficile | |||
| | | | ||
* Neonates (postnatal age > 7 days): 15 mg/kg/24 hr divided q 24 hr IV (< 1,200 g); 15 mg/kg/24 hr divided q 12-18 hr IV (1,200–2,000 g); 30 mg/kg/24 hr divided q 12 hr IV (> 2,000 g) | |||
* Neonates (postnatal age > 7 days): 15 mg/kg/24 hr divided q 24 hr IV (< 1,200 g); 15 mg/kg/24 hr divided q 8-12 hr IV (1,200–2,000 g); 45 mg/kg/24 hr divided q 8 hr IV (> 2,000 g) | |||
* Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV | |||
* C. difficile–associated colitis: 40-50 mg/kg/24 hr divided q 6-8 hr PO; 40-50 mg/kg/24 hr divided q 6-8 hr PO | |||
days | |||
15 mg/kg/24 hr divided q 8-12 hr IV | |||
divided q 8 hr IV | |||
Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV | |||
40-50 mg/kg/24 hr divided q 6-8 hr PO | |||
| | | | ||
* Ototoxicity | |||
* Nephrotoxicity | |||
|} | |} |
Latest revision as of 07:03, 3 June 2015
Antibiotic Agent | Antimicrobial Spectrum | Dosing Information | Notable Adverse Reaction |
---|---|---|---|
Amikacin |
|
|
|
Amoxicillin |
|
|
|
Amoxicillin-Clavulanate |
|
|
|
Ampicillin |
|
|
|
Ampicillin-Sulbactam |
|
|
|
Azithromycin |
|
|
|
Aztreonam |
|
|
|
Carbenicillin |
|
|
|
Cefaclor |
|
|
|
Cefadroxil |
|
|
|
Cefazolin |
|
|
|
Cefdinir |
|
|
|
Cefepime |
|
|
|
Cefixime |
|
|
|
Cefoperazone |
|
|
|
Cefotaxime |
|
|
|
Cefotetan |
|
|
|
Cefoxitin |
|
|
|
Cefpodoxime |
|
|
|
Cefprozil |
|
|
|
Ceftazidime |
|
|
|
Ceftiaoxime |
|
|
|
Ceftriaxone |
|
|
|
Cefuroxime |
|
|
|
Cephalexin |
|
|
|
Cephradine |
|
|
|
Chloramphenicol |
|
|
|
Ciprofloxacin |
|
|
|
Clarithromycin |
|
|
|
Clindamycin |
|
|
|
Cloxacillin |
|
|
|
Trimethoprim-Sulfamethoxazole |
|
|
|
Demeclocycline |
|
|
|
Dicloxacillin |
|
|
|
Doripenem |
|
|
|
Doxycycline |
|
|
|
Erythromycin |
|
|
|
Gentamicin |
|
|
|
Imipenem-Cilastatin |
|
|
|
Linezolid |
|
|
|
Loracarbef |
|
|
|
Meropenem |
|
|
|
Metronidazole |
|
|
|
Mezlocillin |
|
|
|
Mupirocin |
|
|
|
Nafcillin |
|
|
|
Nalidixic acid |
|
|
|
Neomycin |
|
|
|
Nitrofurantoin |
|
|
|
Ofloxacin |
|
|
|
Oxacillin |
|
|
|
Penicillin G |
|
|
|
Penicillin G, benzathine |
|
|
|
Penicillin G, procaine |
|
|
|
Penicillin V |
|
|
|
Piperacillin |
|
|
|
Piperacillin-Tazobactam |
|
|
|
Quinupristin-Dalfopristin |
|
|
|
Sulfadiazine |
|
|
|
Sulfamethoxazole |
|
|
|
Sulfisoxazole |
|
|
|
Ticarcillin |
|
|
|
Ticarcillin-Clavulanate |
|
|
|
Tigecycline |
|
|
|
Tobramycin |
|
|
|
Trimethoprim |
|
|
|
Vancomycin |
|
|
|